Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain^†

A long-term, open-label safety study

1. Sharon M. Weinstein MD^1,‡,*,
2. John Messina PharmD²,
3. Fang Xie PhD²

Article first published online: 16 APR 2009

DOI: 10.1002/cncr.24279

Copyright © 2009 American Cancer Society

Issue

1. ^†

   The authors thank the investigators: Jacob Abraham, MD; Andrea Baxter, MD; Patrick Beatty, MD; Ali Ben-Jacob, MD; Donald Berdeaux, MD; Debra Brandt, MD; Donald Brooks, MD; Daniel Buffington, MD; Jennifer Caskey, MD; Veena Charu, MD; Michael Drass, MD; David Ellison, MD; Orlando Florete, MD; Nashat Gabrail, MD; Gregory Guzley, MD; Martin E. Hale, MD; Youssef Hanna, MD; Mohamed Haq, MD; Jeffrey Hines, MD; Timothy Houden, MD; Haresh Jhangiani, MD; Edward Kaplan, MD; Ronald Kawauchi, MD; Christine Laramee, MD; Gary Lee, MD; Luis A. Meza, MD; Johnny Nacilla, MD; Srinivas Nalamachu, MD; Ravi Patel, MD; John Peppin, DO; Dat Pham, MD; J. Talisman Pomeroy, MD; Russell Portenoy, MD; Richard Rauck, MD; Prabhakara Reddy, MD; Evangeline Reyes, MD; John Roberts, MD; Marc Saltzman, MD; Thalia Segal, MD; Neal Slatkin, MD; Scott Sonnier, MD; Raymond Sorensen, MD; Forrest Swan, MD; Donald Taylor, MD; Howard Terebelo, MD; Rajbala Thakur, MD; John Thropay, MD; James Weick, MD; and Michael Wertheim, MD.